| Survival: | 6.8 months |
| Toxicity Grade: | 5 |
| Treatments: | Chemotherapy |
| Drugs: | |
| Country: | United States |
| City/State/Province: | St. Louis, MO |
| Hospital: | Washington University School of Medicine |
| Journal: | Link |
| Date: | 3/2005 |
| Description: |
| Patients: This Phase II study involved 43 patients with advanced mesothelioma. Thirty-nine patients were men and four were women. The median age was 72 years. Treatment: The treatment consisted of one chemotherapeutic agent: gefitinib. Toxicity: One patient died during this study of respiratory failure. Grade 3-4 toxicities included dehydration, diarrhea, nausea, and vomiting. Results: The median overall survival was 6.8 months. Twenty-four patients responded to treatment (1 complete response, 1 partial response). However, the authors concluded, “gefitinib was not active in malignant mesothelioma.” Correspondence: Ramaswamy Govindan |